CA2304473A1 - Inhibiteurs de la transferase farnesyle proteine - Google Patents

Inhibiteurs de la transferase farnesyle proteine Download PDF

Info

Publication number
CA2304473A1
CA2304473A1 CA002304473A CA2304473A CA2304473A1 CA 2304473 A1 CA2304473 A1 CA 2304473A1 CA 002304473 A CA002304473 A CA 002304473A CA 2304473 A CA2304473 A CA 2304473A CA 2304473 A1 CA2304473 A1 CA 2304473A1
Authority
CA
Canada
Prior art keywords
tetrahydro
benzodiazepine
compound
naphthalenylcarbonyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002304473A
Other languages
English (en)
Inventor
Rajeev S. Bhide
Charles Z. Ding
John T. Hunt
Katerina Leftheris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2304473A1 publication Critical patent/CA2304473A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Inhibition de la transférase farnésyle qui est une enzyme impliquée dans l'expression de l'oncogène ras, cette inhibition s'effectuant à l'aide des composés ayant les formules (I) et (II), leurs énantiomères, diastéréomères et leurs sels, promédicaments et solvates pharmaceutiquement acceptables qui inhibent la transférase farnésyle protéine, laquelle est une enzyme impliquée dans l'expression de l'oncogène ras.
CA002304473A 1997-09-29 1998-09-16 Inhibiteurs de la transferase farnesyle proteine Abandoned CA2304473A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6082397P 1997-09-29 1997-09-29
US60/060,823 1997-09-29
PCT/US1998/019315 WO1999018951A1 (fr) 1997-09-29 1998-09-16 Inhibiteurs de la transferase farnesyle proteine

Publications (1)

Publication Number Publication Date
CA2304473A1 true CA2304473A1 (fr) 1999-04-22

Family

ID=22031967

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002304473A Abandoned CA2304473A1 (fr) 1997-09-29 1998-09-16 Inhibiteurs de la transferase farnesyle proteine

Country Status (5)

Country Link
EP (1) EP1027042A4 (fr)
JP (1) JP2001519387A (fr)
AU (1) AU735366B2 (fr)
CA (1) CA2304473A1 (fr)
WO (1) WO1999018951A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458783B1 (en) * 1997-09-29 2002-10-01 Bristol-Myers Squibb Company Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
CN1636011A (zh) 1998-12-24 2005-07-06 杜邦药品公司 作为Aβ蛋白产生抑制剂的琥珀酰氨基苯并二氮杂䓬
AU5497000A (en) * 1999-06-18 2001-01-09 Ramot University Authority For Applied Research And Industrial Development Ltd. Non-malignant disease treatment with ras antagonists
US20020115696A1 (en) 1999-06-18 2002-08-22 Yoel Kloog Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
FR2796943A1 (fr) * 1999-07-30 2001-02-02 Aventis Pharma Sa Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
EP1222176A1 (fr) 1999-10-08 2002-07-17 Bristol-Myers Squibb Pharma Company AMINO SULFONAMIDES DE LACTAME UTILISES COMME INHIBITEURS DE LA PRODUCTION DE PROTEINE A$g(b)
EP1261610A2 (fr) 2000-02-17 2002-12-04 Bristol-Myers Squibb Pharma Company CARBOCYCLES ET HETEROCYCLES SUCCINOYLAMINO UTILISES EN TANT QU'INHIBITEURS DE LA PRODUCTION DE LA PROTEINE A$g(b)
EP1268434A1 (fr) 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Lactames cycliques utiles en tant qu'inhibiteurs de la production de proteine a-beta
MXPA02009755A (es) 2000-04-03 2003-03-27 Bristol Myers Squibb Pharma Co Lactamas ciclicas como inhibidores de la produccion de proteina a-beta.
WO2001077086A1 (fr) 2000-04-11 2001-10-18 Dupont Pharmaceuticals Company LACTAMES SUBSTITUES UTILISES EN TANT QU'INHIBITEURS DE PRODUCTION DE PROTEINE A$g(b)
IL147629A0 (en) 2000-06-01 2002-08-14 Bristol Myers Squibb Pharma Co LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
EP1443936A4 (fr) * 2001-11-13 2006-01-11 Bristol Myers Squibb Co Procede de preparation de composes de 3,7-disubstitue-2,3,4,5- tetrahydro-1h-1,4-benzodiazepine
CA2559285A1 (fr) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Traitement des synucleinopathies
JP2008539276A (ja) * 2005-04-27 2008-11-13 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法
BRPI0811204A8 (pt) 2007-05-10 2015-09-22 Bristol Myers Squibb Co Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina
WO2013023059A2 (fr) 2011-08-10 2013-02-14 Lankenau Institute For Medical Research Méthodes et compositions pour le traitement de maladies auto-immunes et inflammatoires
BR122019007990B1 (pt) 2013-11-18 2021-05-04 Forma Therapeutics, Inc Composto, e, composição farmacêutica
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
PL3445744T3 (pl) * 2016-04-18 2022-02-07 Vivoryon Therapeutics Ag Nowe inhibitory mepryny alfa i beta
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase

Also Published As

Publication number Publication date
AU735366B2 (en) 2001-07-05
EP1027042A1 (fr) 2000-08-16
WO1999018951A1 (fr) 1999-04-22
EP1027042A4 (fr) 2004-08-18
AU9488698A (en) 1999-05-03
JP2001519387A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
AU735366B2 (en) Inhibitors of farnesyl protein transferase
AU709409B2 (en) Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
US6455523B1 (en) Inhibitors of farnesyl protein transferase
US6387926B1 (en) Inhibitors of farnesyl protein transferase
US6458783B1 (en) Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
US10053431B2 (en) Tetrahydro-benzodiazepinones
US6156746A (en) 1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents
US7074921B2 (en) Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds
MXPA99011408A (en) Inhibitors of farnesyl protein transferase
CZ469699A3 (cs) Inhibitory farnesylproteintransferázy
LT4552B (lt) Farnezilproteintransferazės inhibitoriai

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead